Application of Liposomal Amphotericin B (L-AmB) in Veno-Venous Extracorporeal Membrane Oxygenation (VV-ECMO) Patients with Invasive Fungal Disease (IFD)

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2500109067

Enrollment

Unknown

Registered

2025-09-11

Start date

2025-10-01

Completion date

Unknown

Last updated

2025-09-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Invasive Fungal Disease (IFD)

Interventions

Experimental group:Experimental group: VV-ECMO patients who develop IFD and receive adjusted-dose (1–2× standard dose) L-AmB.

Control group:Non-ECMO patients receiving standard-dose L-AmB for IFD.

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Critically ill adults aged >18 and =7 days.

Exclusion criteria

Exclusion criteria: 1. Any confirmed or suspected state of immunosuppression or immunodeficiency and pregnancy; 2. Patients with advanced malignant tumors; 3. Patients estimated to die within 48 hours; 4. Patients participating in other clinical studies

Design outcomes

Primary

Measure	Time frame
The peak total plasma AmB concentration measured on day 2 of continuous L-AmB therapy;The mean L-AmB dose;	—

Secondary

Measure	Time frame
Favorable response;Duration of ICU stay;Incidence of adverse events;	—

Countries

China

Contacts

Public ContactXing Jinyan

The Affiliated Hospital of Medical College Qingdao University, China

xingjy@qdu.edu.cn+86 532 8291 1852

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026